The mechanism underlying the prolonged remission observed in one patient with an exceptional response therefore remains unknown but it is possible that this patient belongs to a small subgroup of AML and ALL patients in which the PI3K pathway functions as oncogenic driver at the level of LSCs. The gene discussed is PIK3CD; the disease is acute lymphoblastic leukemia.